Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 22%
Hold 50%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings (ZBH) demonstrates a positive outlook due to its significant market share growth in the global reconstructive market, with a year-over-year increase of approximately 20 basis points, bringing its share to 32.9%. The company reported strong sales performance in its knee and hip segments, with knee sales reaching $911 million and hip sales totaling $555 million, both exceeding consensus estimates and showing improvements from the previous quarter. Additionally, the firm experienced operational margin expansion, building from a reported 28.6% for FY24, reflecting its effective cost management and growth strategies.

Bears say

The analysis of Zimmer Biomet Holdings (ZBH) highlights a concerning trend of declining organic revenue growth, marked by a slowdown over the past eight quarters that is expected to persist into 2026. Additionally, the underperformance of Paragon 28 and limited contributions from new product launches have constrained potential growth, which is now projected to slump to 2% or less. Compounding these issues, ZBH has experienced a deterioration in its operating margin, exacerbated by increased selling, general, and administrative (SG&A) expenses, indicating challenges that could lead to below-consensus earnings.

ZBH has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 22% recommend Buy, 50% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 18 analysts, ZBH has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.